Caxton Associates LP Neurocrine Biosciences Inc Transaction History

Caxton Associates LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $53,260 - $58,278	-407 Reduced 2.2%	18,121 $2.49 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $2.42 Million - $2.66 Million	18,528 New	18,528 $2.56 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $199,993 - $238,110	1,874 Added 62.57%	4,869 $581,000
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $275,629 - $322,890	2,995 New	2,995 $318,000
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $914,481 - $1.29 Million	-9,510 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $809,205 - $1.24 Million	9,510 New	9,510 $1.16 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $305,021 - $461,979	-4,061 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $352,494 - $481,512	4,061 New	4,061 $437,000

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.